Atea Pharmaceuticals, Inc.
AVIRHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, Atea Pharmaceuticals, Inc. (AVIR) is listed under Biotechnology. With a market capitalization of $467.6M, it sits in small-cap territory. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Market Cap
$467.6M
Beta
0.28
P/E (TTM)
—
P/E (Fwd)
-3.94
EPS (TTM)
$-2.08
EPS (Fwd)
$-1.48
ROE
-58.1%
ROA
-36.7%
Cash
$219.5M
Total Debt
$424,000
Free CF
-$92.8M
52W Change
84.5%
Annual Financials
Cash vs Debt
Where AVIR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, AVIR finished 14.00% above its 150-day moving average ($5.00) and 24.45% above its 200-day moving average ($4.58). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AVIR overbought or oversold?
At the September 3, 2026 close, AVIR's RSI(14) was 70.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $219.5M in cash and $424K in debt, AVIR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$92.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -58.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.28 suggests AVIR is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, AVIR has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Atea Pharmaceuticals, Inc.'s trajectory.